Search company, investor...

Founded Year

2016

Stage

Series A | Alive

Total Raised

$6.73M

Last Raised

$3.53M | 2 yrs ago

About Kantum Pharma

Kantum is developing a specific AKI therapy to help critical care clinicians prevent hundreds of thousands of deaths from AKI. This targeted therapy will be supported by the development of a diagnostic test for AKI.

Headquarters Location

75 S Main St #7-160

Concord, New Hampshire, 03301,

United States

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Kantum Pharma Patents

Kantum Pharma has filed 4 patents.

The 3 most popular patent topics include:

  • Dopamine agonists
  • EC 2.4.1
  • Kidney diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/16/2019

Kidney diseases, EC 2.4.1, Organ transplant recipients, Nephrology, Dopamine agonists

Application

Application Date

4/16/2019

Grant Date

Title

Related Topics

Kidney diseases, EC 2.4.1, Organ transplant recipients, Nephrology, Dopamine agonists

Status

Application

Latest Kantum Pharma News

Most patients unaware of how race is used to make risk assessments, guide clinical care

Feb 24, 2023

New study provides an important contribution to the ongoing discussions about racism in medicine Boston University School of Medicine (Boston)— Algorithms that incorporate race as a modifying factor to guide clinical decision-making have recently been criticized for propagating racial bias in medicine. The calculation of lung or kidney function are examples of equations that have different diagnostic parameters depending on an individual’s race. While these clinical measures have multiple implications for care, patients’ awareness of and their perspectives on the application of such algorithms is unknown. To examine patients’ perspectives on race and the use of race-based algorithms in clinical decision-making, researchers from Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center (BMC) undertook a study to investigate patients’ perspectives on race, racism and the use of race-based algorithms in clinical decision-making. “We learned that patients were generally unaware of the widespread use, and misuse of race in medicine and also elicited differing perspectives on race and racial discrimination in healthcare settings,” explained corresponding author Insa Marie Schmidt, MD, MPH, assistant professor of medicine. “For example, the use of race to calculate pulmonary function can reduce the likelihood that Black patients receive disability support for lung diseases.” To examine patients’ perspectives, the researchers conducted semi-structured, qualitative interviews. Most study participants were not cognizant of how race has been used to make risk assessments and guide clinical care. Experiences described by non-white participants ranged from micro-aggressions to overt acts of racism, including perceived racist encounters with healthcare providers. In addition, patients spoke of a deep mistrust in the healthcare system as a major barrier to equitable care. According to the researchers these findings highlight the deleterious effects of racism on health and suggest that focusing research on patients and their lived experiences is crucial to inform the development of anti-racist policies and regulatory agendas. “We hope this study will ultimately highlight the need to center the voices of historically marginalized and minoritized patients when designing research aimed at addressing racism in medicine,” adds Schmidt. I.M.S. is supported by the American Philosophical Society Daland Fellowship in Clinical Investigation. I.M.S. and Merav S. are supported by the Social Science Research Council grant SSRC-4393. S.S.W. is supported by NIH grants UH3DK114915, U01DK085660, U01DK104308, R01DK103784, and R21DK119751. Note to Editor: S.S.W. reports personal fees from Public Health Advocacy Institute, CVS, Roth Capital Partners, Kantum Pharma, Mallinckrodt, Wolters Kluewer, GE Health Care, GSK, Allena Pharmaceuticals, Mass Medical International, Barron and Budd (vs. Fresenius), JNJ, Venbio, Strataca, Takeda, Cerus, Pfizer, Bunch and James, Harvard Clinical Research Institute (aka Baim), Oxidien, Sironax, Metro Biotechnology, Biomarin, and Bain. N.D.E is a full-time employee of Fresenius Medical Care. E.C.M. is also employed by the American Medical Association in the Center for Health Equity. All other authors have nothing to disclose. Journal COI Statement S.S.W. reports personal fees from Public Health Advocacy Institute, CVS, Roth Capital Partners, Kantum Pharma, Mallinckrodt, Wolters Kluewer, GE Health Care, GSK, Allena Pharmaceuticals, Mass Medical International, Barron and Budd (vs. Fresenius), JNJ, Venbio, Strataca, Takeda, Cerus, Pfizer, Bunch and James, Harvard Clinical Research Institute (aka Baim), Oxidien, Sironax, Metro Biotechnology, Biomarin, and Bain. N.D.E is a full-time employee of Fresenius Medical Care. E.C.M. is also employed by the American Medical Association in the Center for Health Equity. All other authors have nothing to disclose. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system. Media Contact

Kantum Pharma Frequently Asked Questions (FAQ)

  • When was Kantum Pharma founded?

    Kantum Pharma was founded in 2016.

  • Where is Kantum Pharma's headquarters?

    Kantum Pharma's headquarters is located at 75 S Main St #7-160, Concord.

  • What is Kantum Pharma's latest funding round?

    Kantum Pharma's latest funding round is Series A.

  • How much did Kantum Pharma raise?

    Kantum Pharma raised a total of $6.73M.

  • Who are the investors of Kantum Pharma?

    Investors of Kantum Pharma include Broadview Ventures, 10X Venture Partners, New Hampshire Tech Alliance and Mill Works Fund.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.